AWH

Aspira Women`s Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.680
+0.130
+3.66%
After Hours: 3.680 0 0.00% 16:00 10/23 EDT
OPEN
3.540
PREV CLOSE
3.550
HIGH
3.790
LOW
3.510
VOLUME
312.35K
TURNOVER
--
52 WEEK HIGH
5.78
52 WEEK LOW
0.5310
MARKET CAP
382.82M
P/E (TTM)
-24.3225
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Aspira Womens Health Inc. Announces it is now an Anthem BlueCross BlueShield of Georgia Participating Provider
Over 173M lives covered with the addition of Anthem BlueCross BlueShield of Georgia, which covers approximately 3.3 million members across the stateAUSTIN, Texas, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical-based women’s health company, today announced that it has further expanded network access for both OVA1® and ASPIRA GenetiXSM Testing. Aspira is now a participating provider for all PAR/PPO and Medicare Advantage PPO products of Anthem BlueCross BlueShield of Georgia, an independent licensee of the Blue Cross Blue Shield Association. “We are pleased that we are now a participating provider with BlueCross BlueShield of Georgia network,” said Valerie Palmieri, President and CEO of Aspira Women’s Health Inc. "This is a considerable plan as it represents close to 30% of Georgia’s population. We can now provide more physicians and patients access to OVA1 and GenetiX, which will help ensure that women of ALL ages, stages, and ethnicities have the best solutions available to assess their personalized risk of ovarian cancer at the earliest stage when it matters most.”About Aspira Women’s Health Inc. Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXTM testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEXTM and EndoCheckTM. Visit our website for more information at www.aspirawh.com.Investor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577 Arr@lifesciadvisors.com
GlobeNewswire · 10/14 13:00
Aspira Womens Health, Inc. to Present at MicroCap Rodeo Best Ideas Bowl October 13-16
GlobeNewswire · 10/09 13:00
The MicroCap Rodeo Best Ideas Bowl 2020; October 13-16, 2020
NEW YORK, NY / ACCESSWIRE / October 8, 2020 / The MicroCap Rodeo continues this year with its first virtual event set for October 13-16, 2020.
ACCESSWIRE · 10/08 19:30
Key Things To Understand About Aspira Women's Health's (NASDAQ:AWH) CEO Pay Cheque
Valerie Palmieri has been the CEO of Aspira Women's Health Inc. (NASDAQ:AWH) since 2015, and this article will examine...
Simply Wall St. · 10/06 12:57
Aspira Women’s Health has Emerged as a Global Leader for Innovations in Ovarian Cancer Risk Assessment Starting with OVA1®plus, OVANex™, OVAInherit™ and ASPiRA GenetiX℠
During Ovarian Cancer Awareness Month, Aspira Women’s Health highlights its innovative mission and leadership in ovarian cancer detection and risk assessment using protein and genetics solutions
News Direct · 09/28 12:30
Aspira Womens Health, Inc. to Host Key Opinion Leader Call on Ovarian Cancer Diagnostics, Innovation Pipeline, and Rebranding Initiatives
Call on Friday, September 25, 2020 @ 12pm Eastern TimeAUSTIN, Texas, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will host a key opinion leader (KOL) call on ovarian cancer diagnostics, innovation
GlobeNewswire · 09/15 22:01
Aspira Women’s Health, Inc. to Present at Cantor Virtual Healthcare Conference
AUSTIN, Texas, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced management will participate in the 2020 Cantor Virtual Healthcare Conference taking place on September 15-17, 2020. Valerie Palmieri, President and
GlobeNewswire · 09/08 15:44
Is Aspira Women's Health Inc. (NASDAQ:AWH) Popular Amongst Insiders?
The big shareholder groups in Aspira Women's Health Inc. (NASDAQ:AWH) have power over the company. Insiders often own...
Simply Wall St. · 08/22 15:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AWH. Analyze the recent business situations of Aspira Women`s Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AWH stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 76
Institutional Holdings: 30.40M
% Owned: 29.22%
Shares Outstanding: 104.03M
TypeInstitutionsShares
Increased
15
4.01M
New
43
2.41M
Decreased
4
197.50K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.56%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Independent Director
James LaFrance
President/Chief Executive Officer/Director
Valerie Palmieri
Chief Financial Officer
Robert Beechey
Independent Director
James Burns
Independent Director
Nancy Cocozza
Independent Director
Veronica Jordan
Independent Director
David Schreiber
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
05/22/2017
Dividend USD 0
07/07/2017
05/22/2017
Special Dividend USD 5
07/07/2017
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AWH
Aspira Women’s Health Inc., formerly Vermillion, Inc., is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1, Overa and OVA1PLUS risk of malignancy tests for ovarian cancer. The Company also sells a product for genetic testing for specific women’s health diseases, called ASPiRA GenetiX, with a core focus on ovarian cancer. OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor before planned surgery. The Overa is a second-generation biomarker panel intended to maintain its product’s sensitivity while improving specificity. OVA1PLUS is a service offering combining its OVA1 and Overa products, designed to enhance accuracy and reduce false elevations in the intermediate-risk area.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aspira Women's Health Inc stock information, including NASDAQ:AWH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AWH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AWH stock methods without spending real money on the virtual paper trading platform.